What is Vanta Bioscience share price return in the past 10 years?

Data is not available for this company

Vanta Bioscience Ltd - Stock Valuation and Financial Performance

Name: Vanta Bioscience
Brand: Vanta Bioscience

BSE: 540729 | NSE: | Business Support | Small Cap

Place order

Vanta Bioscience Share Price

₹63 1.49 2.42%
as on 26-Apr'24 16:01

DeciZen - make an informed investing decision on Vanta Bioscience

Based on:

Data

M-Cap below 100cr DeciZen not available

Vanta Bioscience stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

39.8 Cr.

52-wk low:

52-wk high:

101.6

Is Vanta Bioscience Ltd an attractive stock to invest in?

1. Is Vanta Bioscience Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vanta Bioscience Ltd is a below average quality company.

2. Is Vanta Bioscience Ltd undervalued or overvalued?

The key valuation ratios of Vanta Bioscience Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Vanta Bioscience Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vanta Bioscience Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Vanta Bioscience:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	0%	0%	0%	0%	0.6%	5.5%	6.2%	4.9%	3.6%	-4.6%	-
Value Creation Index ⓘ	NA	NA	NA	NA	-1.0	-0.6	-0.6	-0.7	-0.7	-1.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	0	3.9	12.1	13.7	9.8	9.4	5.2	5
Sales YoY Gr.	-	NA	NA	NA	NA	211.3%	13.6%	-28.4%	-4.8%	-44.7%	-
Adj EPS ⓘ	0	0	0	0	-0	0.9	1.4	0.8	0.1	-6.7	-6.7
YoY Gr.	-	NA	NA	NA	NA	NA	64.4%	-45.5%	-85.9%	-6209.1%	-
BVPS (₹) ⓘ	0	0	0	16.9	29	35.2	37.1	37.9	38	31.3	31.3
Adj Net Profit ⓘ	0	0	0	0	0	0.6	0.9	0.5	0.1	-4.2	-4
Cash Flow from Ops. ⓘ	0	0	0	-0.3	-6.8	-0.1	3.2	11	6.7	0.6	-
Debt/CF from Ops. ⓘ	0	0	0	-28.3	-1.7	-215.7	4.5	1.6	3.1	40	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	5.9%	-27.8%	-44.7%
Adj EPS ⓘ	NA	NA	-267.5%	-6209.1%
BVPSⓘ	NA	1.6%	-5.6%	-17.7%
Share Price	-	-20.1%	-28.2%	20.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	0	-0.1	2.8	4	2.1	0.3	-19.4	-21.5
Op. Profit Mgn % ⓘ	0	26.6	27.2	31.5	40.2	36.4	-9.2	NAN
Net Profit Mgn % ⓘ	0	-0.2	4.6	6.6	5	0.7	-82	-81.9
Debt to Equity ⓘ	1.2	0.7	0.6	0.6	0.7	0.9	1.3	-
Working Cap Days ⓘ	0	235	251	390	577	490	791	0
Cash Conv. Cycle ⓘ	0	141	193	319	464	328	484	0

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years -27.77%

Debt to equity has increased versus last 3 years average to 1.30

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Vanta Bioscience Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-6.7	-10.3
TTM Sales (₹ Cr.)	5.2	6.3
BVPS (₹.) ⓘ	31.3	27.8
Reserves (₹ Cr.) ⓘ	13	11
P/BV ⓘ	2.01	2.27
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	37.00 / 101.64
All Time Low / High (₹)	37.00 / 195.50
Market Cap (₹ Cr.)	39.8
Equity (₹ Cr.)	6.3
Face Value (₹)	10
Industry PE ⓘ	45

Management X-Ray of Vanta Bioscience:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Vanta Bioscience

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Vanta Bioscience

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	0	3.88	12.08	13.72	9.82	9.35	5.17
Operating Expenses ⓘ	0	2.85	8.81	9.41	5.92	5.95	5.65
Manufacturing Costs	0	0.31	1.17	1.24	0.69	0.74	0.72
Material Costs	0	0.32	1.40	1.18	0.82	0.62	0.68
Employee Cost	0	1.61	2.90	3.79	2.51	2.57	2.75
Other Costs ⓘ	0	0.60	3.33	3.19	1.91	2.01	1.49
Operating Profit ⓘ	0	1.03	3.27	4.32	3.89	3.40	-0.48
Operating Profit Margin (%)	-	26.6%	27.1%	31.5%	39.7%	36.4%	-9.2%
Other Income ⓘ	0	0.05	0.23	0.11	0.02	0.17	0.63
Interest ⓘ	0	0.20	1.69	1.95	2.06	2.11	3.11
Depreciation ⓘ	0	0.57	0.71	1.19	1.25	1.32	1.25
Exceptional Items ⓘ	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0	0.31	1.10	1.29	0.61	0.14	-4.21
Tax ⓘ	0	0.29	0.40	0.31	0.13	0.06	0.03
Profit After Tax	0	0.03	0.69	0.98	0.47	0.08	-4.24
PAT Margin (%)	-	0.7%	5.7%	7.1%	4.8%	0.8%	-81.9%
Adjusted EPS (₹)	0.0	0.1	1.1	1.6	0.8	0.1	-6.7
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	6.15	16.59	22.25	23.44	23.91	23.99	19.74
Share Capital ⓘ	3.65	5.73	6.31	6.31	6.31	6.31	6.31
Reserves ⓘ	2.50	10.86	15.93	17.13	17.60	17.68	13.43
Minority Interest	0	0	0	0	0	0	0
Debt	7.50	10.48	12.17	12.31	13.30	17.14	22.55
Long Term Debt	7.50	9.98	12.17	10.43	10.77	15.64	20.84
Short Term Debt	0	0.50	0	1.88	2.53	1.50	1.71
Trade Payables	0	0.19	0.46	0.49	0.47	1.47	2.36
Others Liabilities ⓘ	0.10	1.93	3.25	5.50	8.62	7.85	6.98
Total Liabilities ⓘ	13.75	29.19	38.12	41.74	46.30	50.44	51.64
Fixed Assets
Gross Block	12.95	18.06	19.18	23.23	33.11	41.16	43.69
Accumulated Depreciation	0	0.57	1.28	2.47	3.72	5.04	6.29
Net Fixed Assetsⓘ	12.95	17.49	17.90	20.76	29.39	36.12	37.40
CWIP ⓘ	0	2.34	3.70	0	0	0	0
Investmentsⓘ	0	4.50	3.95	3	3	3	3
Inventories	0	3.02	9.24	14.01	9.76	7.24	7.16
Trade Receivables	0	0.33	1.56	1.36	1.98	0.72	1.92
Cash Equivalents	0.44	0.09	0.28	0.09	0.07	0.07	0.07
Others Assetsⓘ	0.36	1.42	1.48	2.54	2.10	3.30	2.09
Total Assets ⓘ	13.75	29.19	38.12	41.74	46.30	50.44	51.64

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	-0.26	-6.75	-0.06	3.17	11.01	6.70	0.64
PBT ⓘ	0	0.31	1.10	1.29	0.61	0.14	-4.21
Adjustment ⓘ	0	0.73	2.40	3.14	3.29	3.43	4.36
Changes in Working Capital ⓘ	-0.26	-7.8	-3.56	-1.26	7.11	3.13	0.49
Tax Paid ⓘ	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-12.95	-7.53	-4.48	-1.35	-9.86	-8.05	-2.53
Capex	-12.95	-2.60	-2.48	-0.35	-0.86	-8.05	-2.53
Net Investments	0	-0.08	0	0	0	0	0
Others ⓘ	0	-4.86	-2	-1	-9	0	0
Cash Flow From Financing Activityⓘ	13.66	13.93	4.73	-2.02	-1.17	1.35	1.88
Net Proceeds from Shares ⓘ	6.15	10.41	4.96	0	0	0	0
Net Proceeds from Borrowing ⓘ	7.50	2.48	2.19	-1.74	0.34	1.40	5.20
Interest Paid ⓘ	0	-0.16	-1.69	-1.95	-2.06	-2.11	-3.11
Dividend Paid ⓘ	0	0	0	0	0	0	0
Others ⓘ	0.01	1.20	-0.73	1.67	0.55	2.07	-0.21
Net Cash Flow ⓘ	0.44	-0.36	0.20	-0.20	-0.02	0	0

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	0	0.24	3.57	4.28	1.99	0.33	-19.37
ROCE (%)	0	2.47	8.81	8.86	6.76	5.24	-2.44
Asset Turnover Ratio	0	0.19	0.37	0.35	0.23	0.19	0.1
PAT to CFO Conversion(x)	N/A	-225	-0.09	3.23	23.43	83.75	N/A
Working Capital Days
Receivable Days	0	30	28	38	61	53	93
Inventory Days	0	277	180	301	432	332	508
Payable Days	0	220	85	147	213	566	1,023

Vanta Bioscience Ltd Stock News

Vanta Bioscience Ltd FAQs

What is the share price of Vanta Bioscience?

Company share prices are keep on changing according to the market conditions. The closing price of Vanta Bioscience on 26-Apr-2024 16:01 is ₹63.00.

What is the market cap of Vanta Bioscience?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Apr-2024 16:01 the market cap of Vanta Bioscience stood at ₹39.77.

What is the P/E ratio of Vanta Bioscience?

The latest P/E ratio of Vanta Bioscience as of 26-Apr-2024 16:01 is 0.00.

What is the P/B ratio of Vanta Bioscience?

The latest P/B ratio of Vanta Bioscience as of 26-Apr-2024 16:01 is 2.01.

What is the 52-week high and low of Vanta Bioscience?

The 52-week high of Vanta Bioscience is ₹101.6 and the 52-week low is ₹37.00.

What is the TTM revenue of Vanta Bioscience?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vanta Bioscience is ₹5.17 ( Cr.) .

About Vanta Bioscience Ltd

Vanta Bioscience (VBS) was originally incorporated as a private limited company under the Companies Act, 2013 pursuant to a certificate of incorporation issued by the Registrar of Companies, Hyderabad dated April 29, 2016 with the name ‘Vanta Bioscience Private Limited’. Their Company was converted into a public limited company pursuant to approval of the shareholders at an extraordinary general meeting held on February 13, 2017 and consequently, the name of the Company was changed to ‘Vanta Bioscience Limited’ and a fresh certificate of incorporation consequent upon conversion to public limited company was issued by the Registrar of Companies, Hyderabad on March 17, 2017.

One of the major services of VBL is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. The relationship between dose and its effects on the exposed organism is of high significance in toxicology. Toxicology and safety assessment are sometimes used interchangeably and considered as synonymous.

Business area of the company

The company is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition they also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation.

Major Events & Milestones:

2016: Incorporation of the Company.
2017: The Company concluded the purchase of the preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as - Vanta Bioscience? (a toxicology division of Kemin Industries South Asia Private Limited) along with leasehold rights in 4.8 acres of land situated at Plot K2B, SIPCOT Industrial Estate, Gummidipundi, Chennai - 601 201.